Company profile
OKYO Pharma Ltd
NASDAQ:OKYOBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Urcosimod | phase2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06637527 | phase2 | terminated | 2024-10-15 | 2025-04-30 | Okyo Pharma Ltd | The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain |
| NCT05759208 | phase2 | completed | 2023-04-28 | 2023-12-15 | Okyo Pharma Ltd | The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease |
FDA applications (0)
No records yet.